News Channels

04 Dec 2017 BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML
04 Dec 2017 Foresee Pharmaceuticals Announces Results from Phase 1 Clinical Studies
04 Dec 2017 Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression
04 Dec 2017 Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase 3 Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults
04 Dec 2017 Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia
04 Dec 2017 Mustang Bio Announces License Agreement with Harvard University, and Research Collaboration with Beth Israel Deaconess Medical Center, to Develop CRISPR/Cas9-Enhanced CAR T Therapies
04 Dec 2017 La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC‑401 in Patients with Beta Thalassemia
04 Dec 2017 Updated larotrectinib pediatric clinical trial data demonstrate continued durability of response in TRK fusion cancers
04 Dec 2017 Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study
04 Dec 2017 Takeda announces research collaboration in ALS with Montreal Neurological Institute
04 Dec 2017 Xynomic Pharma Initiates Ph 1/2 Trial Combining Abexinostat with Ibrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and Mantle Cell Lymphoma (r/r MCL)
04 Dec 2017 Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting
04 Dec 2017 Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)
04 Dec 2017 Saniona AB: Saniona Selects Preclinical Candidate in GABAA a2/a3 Program for Neuropathic Pain and Chronic Itching
04 Dec 2017 Active Biotech announce results in ARPEGGIO Phase II trial with laquinimod in Primary Progressive MS
04 Dec 2017 Tudorza reduces exacerbations and demonstrates cardiovascular safety in COPD patients
04 Dec 2017 Sanofi's Toujeo® met main objective in head-to-head study versus insulin degludec
04 Dec 2017 Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis
04 Dec 2017 Sanofi ends development of Clostridium difficile vaccine
04 Dec 2017 FDA Approves Amgen's Repatha® (evolocumab) To Prevent Heart Attack And Stroke

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing